【摘要】 为了探讨口服１，２５（ＯＨ）２Ｄ３冲击治疗对腹膜透析患者钙磷代谢及甲状旁腺功能的影响，我们给予３２例ＣＡＰＤ患者口服１．２５（ＯＨ）２Ｄ３大剂量冲击治疗（２－４μｇ／次，每周２次）．另２９例为常规治疗组（０．２５－０．５ｕｇ／ｄ）作为对照组。结果显示，两组患者血钙均明显升主，血磷及血ＡＫＰ均明显降低；ＰＴＨ和ＣＴ在常规治疗组有轻度降低，但无统计学差异；而口服冲击治疗组，ＰＴＨ和ＣＴ则明显降低，且临床症状明显改善，用药过程中未发现明显副作用。上述结果表明，１，２５（ＯＨ）２Ｄ３口服冲击治疗是纠正钙磷代谢紊乱和甲状旁腺功能亢进的较佳疗法，值得推荐。更多还原

【Abstract】 n order to investigate the clinical ef-fects of oral pulse therapy with 1, 25(OH)2D3 on the calcium (Ca), phosphorous(P) metabolism and parathyroidism func-tion of the patients receiving CAPD, highdosage of 1,25(OH)2D3 was given to the 32patients on CAPD ( 2￣ 4 μg , twice a week) ,and regulatory dosage was given to the oth-er 29 patients on CAPD (0. 25￣ 0. 5 μg/d).The results showed serum Ca increased,pand AKP decreased in both groups. In thepatients with regulatory dosage, the serumPTH and CT were reduced lightly, but nosignificant difference as compared to thelevel of pretreatment, while the patientswith oral pulse therapy,serum PTH and CTdecreased significantly, clinical symptomswere also obviously improved ,and no moreside effects were found. The above factssuggested that the oral pulse therapy maybe a good method to correct the disturbenceof Ca ,P and parathyroidism.更多还原